



**AMDL Contact:**  
Kristine Szarkowitz  
Director-Investor Relations  
kszarkowitz@amdl.com  
(714) 380-8832

## AMDL, INC. TO PRESENT AT 5<sup>TH</sup> ANNUAL WINTER TECHNOLOGY CONFERENCE HOSTED BY SECURITY RESEARCH ASSOCIATES, INC.

January 6, 2009 – (www.amdl.com) AMDL, Inc. (Amex: ADL - News), (NYSE Alternext US: ADL - News), a US-based pharmaceutical company with major operations in China, announced today its executive chairman and CEO Mr. Douglas MacLellan will present at the Security Research Associates (SRA) 5<sup>th</sup> Annual Winter Technology Conference on Monday, March 9, 2009.

Through his presentation, Mr. MacLellan will provide conference attendees with an informative investor overview of AMDL, the Company's 2009 business strategy and expanding product portfolio and FY2009 financial projections. The presentation will be held at 12:30 p.m. PST in the *Russian Room* of the Omni Hotel which is located in San Francisco, CA. Conference attendees will include a select group of institutional portfolio managers and analysts, and feature CEO's and CFO's from some of the fastest growing companies in the technology sector.

AMDL was founded in 1987 and operates three distinct business divisions in the US and China that include: (i) *In Vitro* Diagnostics, (ii) Cancer Therapeutics, and (iii) China-based pharmaceutical manufacturing and distribution. Collectively, these business units focus on the development, manufacturing, distribution and sales of high quality generic pharmaceuticals, nutritional supplements, cosmetic and medical diagnostic products in the US, China, Korea, Taiwan and other markets throughout the world.

For the past four consecutive fiscal years, AMDL has achieved 100% or more growth in gross revenues and expects to continue this forward momentum in 2009 as it executes an aggressive business strategy focused on expanding its market presence in China and other select international markets.

In FY2008 AMDL achieved gross revenues between US\$32 to \$36 million vs. \$15 million in FY2007 and net income after foreign currency translation between \$2.4 and \$2.6 million. For FY2007 net loss after foreign currency translation was approximately \$1.26 million.

### Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

**AMDL, Inc.**  
2492 Walnut Ave., Suite 100, Tustin, CA 92780  
Phone 714.505.4460      FAX 714.505.4464  
Web site: <http://www.amdl.com>      E-mail address: [info@amdl.com](mailto:info@amdl.com)



**AMDL Contact:**  
Kristine Szarkowitz  
Director-Investor Relations  
kszarkowitz@amdl.com  
(714) 380-8832

Management issued financial guidance for FY2009 forecasting gross revenues between US\$64 to \$72 million and net income between US\$8 and \$12 million after taxes and before foreign currency translation gains or losses. This guidance ***represents sales for AMDL's China-based operations only*** and does not include sales for the Company's DR-70 (FDP) cancer test or Elleuxe® human placenta extract (HPE) based skin care line. AMDL believes anticipated revenues from these products could potentially result in an additional US\$25 million in gross revenues in FY2009.

AMDL is listed on the American Stock Exchange Alternext US under the symbol "ADL" and employs approximately 510 people in the US and China. Webcasting of all Company presentations during the SRA conference will be accessible following the event by visiting: <http://www.wsw.com/webcast/sra8/>.

**About AMDL:**

Headquartered in Tustin, CA with operations in China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 490 people in the U.S. and China.

**About Security Research Associates, Inc.**

Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA see our web site at [www.sracap.com](http://www.sracap.com) or call us at 415-925-0346.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

**AMDL, Inc.**

2492 Walnut Ave., Suite 100, Tustin, CA 92780  
Phone 714.505.4460 FAX 714.505.4464

Web site: <http://www.amdl.com> E-mail address: [info@amdl.com](mailto:info@amdl.com)